craig-epigeneticage-2019.pdf (346.03 kB)
Epigenetic age acceleration in adolescence associates with BMI, inflammation, and risk score for middle age cardiovascular disease
journal contribution
posted on 2019-07-01, 00:00 authored by R C Huang, K A Lillycrop, L J Beilin, K M Godfrey, D Anderson, T A Mori, S Rauschert, Jeffrey CraigJeffrey Craig, W H Oddy, O T Ayonrinde, C E Pennell, J D Holbrook, P E MeltonAccelerated aging, assessed by adult DNA methylation, predicts cardiovascular disease (CVD). Adolescent accelerated aging might predict CVD earlier. We investigated whether epigenetic age acceleration (assessed age, 17 years) was associated with adiposity/CVD risk measured (ages 17, 20, and 22 years) and projected CVD by middle age. Design: DNA methylation measured in peripheral blood provided two estimates of epigenetic age acceleration: intrinsic (IEAA; preserved across cell types) and extrinsic (EEAA; dependent on cell admixture and methylation levels within each cell type). Adiposity was assessed by anthropometry, ultrasound, and dual-energy x-ray absorptiometry (ages 17, 20, and 22 years). CVD risk factors [lipids, homeostatic model assessment of insulin resistance (HOMA-IR), blood pressure, inflammatory markers] were assessed at age 17 years. CVD development by age 47 years was calculated by Framingham algorithms. Results are presented as regression coefficients per 5-year epigenetic age acceleration (IEAA/EEAA) for adiposity, CVD risk factors, and CVD development.
History
Journal
Journal of clinical endocrinology and metabolismVolume
104Issue
7Pagination
3012 - 3024Publisher
Oxford Univesity PressLocation
Oxford, Eng.Publisher DOI
ISSN
0021-972XeISSN
1945-7197Language
engPublication classification
C1 Refereed article in a scholarly journalCopyright notice
2019, Endocrine SocietyUsage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC